This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kemp, D. M. Articles by Habener, J. F. Search for Related Content PubMed PubMed Citation Articles by Kemp, D. M. Articles by Habener, J. F.

Insulinotropic Hormone Glucagon-Like Peptide 1 (GLP-1) Activation of Insulin Gene Promoter Inhibited by p38 Mitogen-Activated Protein Kinase¹

Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts

Address all correspondence and requests for reprints to: Joel F. Habener, M.D., Laboratory of Molecular Endocrinology, Massachusetts General Hospital, 55 Fruit Street–WEL320, Boston, Massachusetts 02114. E-mail: jhabener{at}partners.org

The insulin gene promoter contains many transcriptional response elements that predispose the gene to a wide range of regulatory signals. Glucagon-like peptide 1 (GLP-1) stimulates insulin gene transcription by intracellular second messenger cascades leading to direct transcription factor activation or to the up-regulation of insulin promoter specific transcription factors. In these studies, we have identified a novel regulatory signaling mechanism acting on the rat insulin 1 promoter (rINS1) in the INS-1 -cell line. In the presence of stimulatory concentrations of GLP-1 (0.1–100 nM) on rINS1 activity, inhibition of p38 mitogen-activated protein kinase (p38 MAPK) using SB 203580 resulted in a marked increase in promoter activity (maximum 3-fold) over GLP-1 alone, as determined by rINS1 promoter-luciferase reporter gene expression. This effect was revealed to be mediated via the cAMP response element (CRE) of rINS1, because site directed mutagenesis of the CRE motif in rINS1 abolished the increased response to SB 203580. Furthermore, inhibition of p38 MAPK uncovered a similar, more pronounced, response in the expression of a generic CRE promoter driven reporter gene. Time course dose-response studies indicate that the p38 MAPK induced inhibitory response may involve expression of immediate early genes (IEGs); maximum repression of rINS1 activity occurred after 4 h of treatment, comparable with regulatory responses by IEGs. In conclusion, these results demonstrate a novel signaling mechanism whereby p38 MAPK represses rINS1 promoter activity in response to GLP-1, suggesting the involvement of a robust regulatory control by p38 MAPK in insulin gene expression. The relevance of this mechanism may be most apparent during periods of cellular stress in which p38 MAPK activity is stimulated. In this regard, reduced insulin expression levels caused by chronic hyperglycemia (glucotoxicity) and/or hyperlipidemia (lipotoxicity) may be a direct consequence of this mechanism.

This article has been cited by other articles:

				S.-J. Kim, C. Nian, and C. H. S. McIntosh Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Modulate {beta}-Cell Chromatin Structure J. Biol. Chem., May 8, 2009; 284(19): 12896 - 12904. [Abstract] [Full Text] [PDF]

				W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]

				J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]

				X. C. Li, O. A. Carretero, Y. Shao, and J. L. Zhuo Glucagon Receptor-Mediated Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in Rat Mesangial Cells: Role of Protein Kinase A and Phospholipase C Hypertension, March 1, 2006; 47(3): 580 - 585. [Abstract] [Full Text] [PDF]

				C. W Hay, E. M Sinclair, G. Bermano, E. Durward, M. Tadayyon, and K. Docherty Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site J. Endocrinol., August 1, 2005; 186(2): 353 - 365. [Abstract] [Full Text] [PDF]

				R. Aikin, D. Maysinger, and L. Rosenberg Cross-Talk between Phosphatidylinositol 3-Kinase/AKT and c-Jun NH2-Terminal Kinase Mediates Survival of Isolated Human Islets Endocrinology, October 1, 2004; 145(10): 4522 - 4531. [Abstract] [Full Text] [PDF]

				B. Zhang, M. Hosaka, Y. Sawada, S. Torii, S. Mizutani, M. Ogata, T. Izumi, and T. Takeuchi Parathyroid Hormone-Related Protein Induces Insulin Expression Through Activation of MAP Kinase-Specific Phosphatase-1 That Dephosphorylates c-Jun NH2-Terminal Kinase in Pancreatic {beta}-Cells Diabetes, November 1, 2003; 52(11): 2720 - 2730. [Abstract] [Full Text] [PDF]

				S. Lim, Y. Zou, and E. Friedman The Transcriptional Activator Mirk/Dyrk1B Is Sequestered by p38alpha /beta MAP Kinase J. Biol. Chem., December 13, 2002; 277(51): 49438 - 49445. [Abstract] [Full Text] [PDF]

				O. G. Chepurny, M. A. Hussain, and G. G. Holz Exendin-4 as a Stimulator of Rat Insulin I Gene Promoter Activity via bZIP/CRE Interactions Sensitive to Serine/Threonine Protein Kinase Inhibitor Ro 31-8220 Endocrinology, June 1, 2002; 143(6): 2303 - 2313. [Abstract] [Full Text] [PDF]

				M. C. Lawrence, H. S. Bhatt, and R. A. Easom NFAT Regulates Insulin Gene Promoter Activity in Response to Synergistic Pathways Induced by Glucose and Glucagon-Like Peptide-1 Diabetes, March 1, 2002; 51(3): 691 - 698. [Abstract] [Full Text] [PDF]

				H. Dadgostar, B. Zarnegar, A. Hoffmann, X.-F. Qin, U. Truong, G. Rao, D. Baltimore, and G. Cheng Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes PNAS, February 5, 2002; 99(3): 1497 - 1502. [Abstract] [Full Text] [PDF]